metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus interferon alpha
	Ipilimumab (10 mg/kg) vs. interferon alpha	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	ipilimumab alone vs. interferon alpha	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-	NaN [NaN; NaN] /10000 0/0 vs. 0/0
versus placebo
	Ipilimumab (10 mg/kg) vs. placebo	1	-1085 [-1703; -468] /10000 162/475 vs. 214/476	-	-1250 [-1877; -623] /10000 234/475 vs. 294/476
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus gp100
	ipilimumab alone vs. gp100	1	-1451 [-2379; -522] /10000 100/137 vs. 119/136	-	-
versus ipilimumab alone
	Ipilimumab (10 mg/kg) vs. ipilimumab alone	1	-529 [-1162; 104] /10000 262/365 vs. 279/362	-130 [-556; 296] /10000 328/365 vs. 330/362	-
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant